Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

ViroVet, a Belgium-based livestock vaccine development spinout of KU Leuven, has raised more than €6m ($6.7m) of initial series B funding from investors including KU Leuven and its seed fund Gemma Frisius Fund. The deal was led by Seventure Partners with supporting contributions from Vives II, the university venture fund for Université catholique de Louvain, in addition to Flemish government-sponsored investment firm PMV and the latter’s venture fund Biotech Fund Flanders. Capricorn Partners and Agri Investment Fund filled out the…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?